Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote & News

Company Profile

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, whi...

Industry: Biotechnology

Sector: Healthcare

Phone: 772 453 2899

Fax: 443 288 4420

Website: www.processapharmaceuticals.com

Address:

601 21st Street, Suite 300, Vero Beach, United States

topstockalerts Jul. 29 at 1:35 AM

$PCSA that was a stronger defense than I anticipated.

0 · Reply

skyrockets_Inc Jul. 29 at 12:31 AM

$PCSA One example below. James Neal alone is getting 62,000 shares that immediately vest on a merger and an additional right to buy 12,000 shares at 4.96/share.......they are about to be RICH.

0 · Reply

skyrockets_Inc Jul. 29 at 12:29 AM

$PCSA Form 4's coming out. All of the B.O.D. and management getting HUGE AMOUNTS of RSUs and additional stock options to purchase at 4.96/share. Very telling!

0 · Reply

MOOSEN Jul. 28 at 11:44 PM

$PCSA HMMM. CLEARING LEVELS OVER THE 1M. EYES.

0 · Reply

ScanStock Jul. 28 at 10:59 PM

Big bulls calling you APUS right now for a run! Looks like they might be right, Loads of bulls moving to APUS now! The next low float stock to squeeze north Look APUS starting to run with fresh news <-- $WBUY $PCSA $ONMD $MATH @@

0 · Reply

ckjamesst Jul. 28 at 9:58 PM

$PCSA thank you lord Jesus been here for 1000 spilts away please run this bad boy to atleast 20+

0 · Reply

ScanStock Jul. 28 at 9:51 PM

0 · Reply

skyrockets_Inc Jul. 28 at 8:37 PM

$PCSA New names you've never seen start popping up on the board after weeks of suspicious volume buying...you know what that means....news drops and then low float PUMP . Fireworks incoming.

0 · Reply

topstockalerts Jul. 28 at 8:09 PM

$PCSA didn’t expect this much follow-through

0 · Reply

Trex28 Jul. 28 at 8:05 PM

$PCSA I have been buying and selling peaks of this stock for 18-months or so. I missed this one as I didn't rebuy on the latest downtrun. But, good luck to all those that rode this new wave. I never trusted the end game...unlike most folks here...I sometimes miss out. I'm just an avg. trader. Most folks on this site NEVER miss. ha ha.

0 · Reply

Processa Pharmaceuticals Proxy statement: Proxy filing

May 7, 2026, 7:00 AM EDT - 2 months ago

Processa Pharmaceuticals Quarterly report: Q1 2026

Mar 18, 2026, 7:00 AM EDT - 4 months ago

Processa Pharmaceuticals Annual report: Q4 2025

Jan 12, 2026, 9:15 AM EST - 7 months ago

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T14:27:11.000Z - 7 months ago

Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study

Jan 5, 2026, 9:15 AM EST - 7 months ago

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

2025-12-17T20:26:47.000Z - 7 months ago

Here’s Why Penny Stock Processa Pharmaceuticals (PCSA) Is Exploding Today

2025-12-17T13:05:52.000Z - 7 months ago

Processa Pharmaceuticals provides update on Phase 2 NGS-Cap

Dec 17, 2025, 8:00 AM EST - 7 months ago

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

2025-12-17T00:50:10.000Z - 8 months ago

Processa Pharmaceuticals Inc trading halted, news pending

Nov 6, 2025, 2:00 AM EST - 9 months ago

Processa Pharmaceuticals Quarterly report: Q3 2025

Nov 5, 2025, 9:15 AM EST - 9 months ago

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

2025-09-02T10:20:11.000Z - 11 months ago

Processa Pharmaceuticals price target lowered to $1 from $2 at H.C. Wainwright

Aug 25, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

2025-08-07T12:47:44.000Z - 1 year ago

Processa secures strategic investment, evaluates crypto strategy

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Aug 7, 2025, 3:00 AM EDT - 1 year ago

Processa Pharmaceuticals Quarterly report: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Jul 9, 2025, 4:15 PM EDT - 1 year ago

Processa Pharmaceuticals Transcript: Status Update

2025-07-01T13:10:33.000Z - 1 year ago

Processa terminates license agreement for PCS3117

Jul 1, 2025, 9:00 AM EDT - 1 year ago

Processa Pharmaceuticals Provides Portfolio and Business Update

2025-06-30T10:58:30.000Z - 1 year ago

Processa Pharmaceuticals price target lowered to $2 from $6 at H.C. Wainwright

2025-06-17T16:35:07.000Z - 1 year ago

Processa sells 28M shares at 25c in public offering

2025-06-17T16:30:08.000Z - 1 year ago

Processa sees 28M shares at 25c in public offering

Jun 17, 2025, 12:26 PM EDT - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 9:00 AM EDT - 1 year ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

2025-06-13T12:05:24.000Z - 1 year ago

Processa Pharmaceuticals files to sell 20.59M shares of common stock, warrants

2025-06-13T12:05:19.000Z - 1 year ago

Processa to engage potential partners, investors at BIO International Convention

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Registration statement: Registration Filing

2025-05-30T13:05:25.000Z - 1 year ago

Processa announces presentation, publication of abstracts at ASCO meeting

May 30, 2025, 9:00 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 12, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

May 7, 2025, 6:00 PM EDT - 1 year ago

Processa Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Mar 20, 2025, 3:00 AM EDT - 1 year ago

Processa Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Feb 7, 2025, 8:00 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 5:17 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

2025-01-28T12:21:04.000Z - 1 year ago

Processa Pharmaceuticals prices $5M at-the-market offering

Jan 27, 2025, 8:30 PM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 7:00 AM EST - 1 year ago

Processa Pharmaceuticals Registration statement: Registration Filing

Jan 16, 2025, 7:00 AM EST - 1 year ago

Processa Pharmaceuticals Registration statement: Registration Filing

2024-12-20T21:35:15.000Z - 1 year ago

Processa Pharmaceuticals files to sell common stock, no amount given

Dec 20, 2024, 7:00 AM EST - 1 year ago

Processa Pharmaceuticals Registration statement: Registration Filing

Oct 30, 2024, 3:00 AM EDT - 1 year ago

Processa Pharmaceuticals Earnings release: Q3 2024

Oct 30, 2024, 3:00 AM EDT - 1 year ago

Processa Pharmaceuticals Quarterly report: Q3 2024

2024-10-02T21:50:16.000Z - 1 year ago

Closing Bell Movers: Levi Strauss down 10% on reduced FY24 revenue view

APO FNF LEVI LUV

2024-10-02T21:00:35.000Z - 1 year ago

Processa Pharmaceuticals jumps 28% after Phase 2 study update

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Processa Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Aug 13, 2024, 3:00 AM EDT - 2 years ago

Processa Pharmaceuticals Earnings release: Q2 2024

Aug 13, 2024, 3:00 AM EDT - 2 years ago

Processa Pharmaceuticals Quarterly report: Q2 2024

Jun 11, 2024, 8:20 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

May 21, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Registration statement: Registration Filing

May 10, 2024, 3:00 AM EDT - 2 years ago

Processa Pharmaceuticals Quarterly report: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Mar 29, 2024, 3:00 AM EDT - 2 years ago

Processa Pharmaceuticals Annual report: Q4 2023

Mar 25, 2024, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Feb 21, 2024, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 1:30 PM EST - 2 years ago

Processa Pharmaceuticals Transcript: The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 14, 2024, 1:00 PM EST - 2 years ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 6, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 1, 2024, 4:22 PM EST - 2 years ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 2 years ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 25, 2024, 11:29 AM EST - 2 years ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 22, 2024, 7:00 AM EST - 2 years ago

Processa Pharmaceuticals Registration statement: Registration Filing

Jan 19, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 18, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 2, 2024, 5:06 PM EST - 2 years ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Dec 29, 2023, 7:00 AM EST - 2 years ago

Processa Pharmaceuticals Registration statement: Registration Filing

Dec 19, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 13, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 13, 2023, 2:00 AM EST - 2 years ago

Processa Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Oct 13, 2023, 1:08 PM EDT - 3 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Oct 5, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Oct 5, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Sep 25, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Sep 6, 2023, 8:15 AM EDT - 3 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 8:05 AM EDT - 3 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 10, 2023, 4:15 PM EDT - 3 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 10, 2023, 3:00 AM EDT - 3 years ago

Processa Pharmaceuticals Quarterly report: Q2 2023

Aug 8, 2023, 8:15 AM EDT - 3 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Jun 14, 2023, 4:15 PM EDT - 3 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

May 22, 2023, 8:05 AM EDT - 3 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 15, 2023, 7:00 AM EDT - 3 years ago

Processa Pharmaceuticals Quarterly report: Q1 2023

May 1, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2023, 8:15 AM EDT - 3 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Apr 14, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals Proxy statement: Proxy Filing

Mar 30, 2023, 4:01 PM EDT - 3 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 30, 2023, 2:30 AM EDT - 3 years ago

Processa Pharmaceuticals Earnings Call Transcript: Q4 2022

Mar 30, 2023, 2:30 AM EDT - 3 years ago

Processa Pharmaceuticals Annual report: Q4 2022

Mar 30, 2023, 2:30 AM EDT - 3 years ago

Processa Pharmaceuticals Earnings release: Q4 2022

Mar 23, 2023, 8:30 AM EDT - 3 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 17, 2023, 8:30 AM EDT - 3 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

topstockalerts Jul. 29 at 1:35 AM

$PCSA that was a stronger defense than I anticipated.

0 · Reply

skyrockets_Inc Jul. 29 at 12:31 AM

$PCSA One example below. James Neal alone is getting 62,000 shares that immediately vest on a merger and an additional right to buy 12,000 shares at 4.96/share.......they are about to be RICH.

0 · Reply

skyrockets_Inc Jul. 29 at 12:29 AM

$PCSA Form 4's coming out. All of the B.O.D. and management getting HUGE AMOUNTS of RSUs and additional stock options to purchase at 4.96/share. Very telling!

0 · Reply

MOOSEN Jul. 28 at 11:44 PM

$PCSA HMMM. CLEARING LEVELS OVER THE 1M. EYES.

0 · Reply

ScanStock Jul. 28 at 10:59 PM

0 · Reply

ckjamesst Jul. 28 at 9:58 PM

$PCSA thank you lord Jesus been here for 1000 spilts away please run this bad boy to atleast 20+

0 · Reply

ScanStock Jul. 28 at 9:51 PM

0 · Reply

skyrockets_Inc Jul. 28 at 8:37 PM

$PCSA New names you've never seen start popping up on the board after weeks of suspicious volume buying...you know what that means....news drops and then low float PUMP . Fireworks incoming.

0 · Reply

topstockalerts Jul. 28 at 8:09 PM

$PCSA didn’t expect this much follow-through

0 · Reply

Trex28 Jul. 28 at 8:05 PM

0 · Reply

smartmoney43 Jul. 28 at 7:56 PM

$PCSA 😍😍

0 · Reply

extrodyne Jul. 28 at 7:54 PM

$PCSA Trending would be nice tomorrow.

0 · Reply

DuvalFish Jul. 28 at 7:45 PM

$PCSA some decent sized buys coming in this power hour. Let’s get some AH news and run this up.

0 · Reply

skyrockets_Inc Jul. 28 at 7:22 PM

$PCSA Up 13% still no news......

1 · Reply

skyrockets_Inc Jul. 28 at 1:58 PM

$PCSA NEWS IMMINENT! First email response I've ever gotten from management in over 7 months of trying. CFO responded to me yesterday and confirmed there will be an update BEFORE August 7 (see below)!

1 · Reply

skyrockets_Inc Jul. 27 at 6:50 PM

$PCSA I asked AI to estimate PCSA valuation in a reverse merger situation given they have no cash, only a shell + NOLs, and assuming the lawsuit gets dropped per the most recent court dockets. See below.

1 · Reply

skyrockets_Inc Jul. 25 at 5:11 PM

$PCSA Nice find SD! The only holdup to the original merger theory here was the NASDAQ shell value as it related to the lawsuit w/ Elion and as of yesterday that has been settled contingent on a 'deal' happening on or before Aug 7. This .....coupled with the insane price action the past 10 days (40% in 10 days) leads me to believe news is IMMINENT. Maybe even Monday morning we hear about a merger. LFG!

1 · Reply

SDBiotechInvestor Jul. 25 at 4:08 PM

$PCSA - Elion lawsuit dropped. News on or before Aug 7.

1 · Reply

ony2k Jul. 25 at 5:22 AM

$PCSA Are those thieves still try to get new money to think they know something?

0 · Reply

skyrockets_Inc Jul. 24 at 5:54 PM

$PCSA the next $NXTC? Chart looks like news could be next week. Monday AM?

0 · Reply

Market Cap	7.17M
Revenue (ttm)	0.00
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	141,500
Avg Vol	68,920
Day's Range	N/A - N/A
Shares Out	2.77M
Stochastic %K	94%
Beta	0.99
Analysts	Strong Sell
Price Target	$25.00